12:00 AM
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Livatag doxorubicin Transdrug: Phase III started

BioAlliance began the open-label, international Phase III ReLive trial to evaluate 20 and 30 mg/m 2 IV Livatag in about 400 patients with HCC resistant or intolerant...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >